Effect of hemoperfusion with HA380 in patients with acute type A aortic dissection

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100053136

Enrollment

Unknown

Registered

2021-11-12

Start date

2022-01-01

Completion date

Unknown

Last updated

2022-09-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type A aortic Dissection

Interventions

Experimental group:HA380 hemoperfusion treatment twice

Control group:Conventional therapy

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1.Aged 18 to 75 years, ATAAD with aortic arch involvement was the main diagnosis (the course of disease was no more than 1 week); 2.Preoperative NYHA II-III cardiac function; 3.Chest radiograph cardiothoracic ratio 2 h and HP time for 6 hours at a time (twice a day, a total of 2 times).

Exclusion criteria

Exclusion criteria: 1.BMI >= 40; 2.Active bleeding or dissection rupture; 3.Pregnancy; 4.Preoperative clinical infection and obvious laboratory infection; 5.Previous heart surgery; 6.Previous liver and kidney dysfunction; 7.Previous cerebrovascular disease; 8.Hereditary connective tissue disease; 9.Preoperative oral anticoagulant and antiplatelet aggregation drugs.

Design outcomes

Primary

Measure	Time frame
Cytokines;	—

Secondary

Measure	Time frame
Duration of mechanical ventilation;Intensive care unit length of stay;Hospitalization expenses;28D survival condition;	—

Countries

China

Contacts

Public ContactLI Tianlong

Sichuan Academy of Medical Sciences (Sichuan Provincial People's Hospital)

ajay1989@126.com+86 18782094080

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026